Novel CNS Biomarkers Summit Europe

Memo

Discover and Validate Ultrasensitive Fluid, Imaging and Digital Measures to Enable Earlier Intervention, Drive Precision and De-Risk CNS Drug Development Europe is rapidly becoming a hub for next-generation CNS biomarker innovation. Landmark approvals of the first Alzheimer's blood tests, rapid advances in ultrasensitive biomarker technologies, and growing investment across European biopharma are accelerating the shift towards precision-driven drug development. However, despite this momentum, more than 80% of late-stage CNS clinical trials still fail to meet their primary endpoints, highlighting the urgent need for biomarkers that can improve patient stratification, demonstrate target engagement and generate earlier signals of efficacy. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging and digital biomarkers for CNS drug development. Join 60+ biomarker, translational medicine, neuroscience, precision medicine, bioanalytical, multi-omics, and clinical development leaders from leading to explore how next-generation biomarkers are being discovered, validated and translated across Alzheimer's disease, Parkinson's disease, ALS, epilepsy, schizophrenia, MSA and other CNS indications Across three days, discover how industry leaders are implementing α-synuclein seed amplification assays, digital cognitive and EEG biomarkers, novel blood-based biomarkers, toxic oligomer assays and multimodal biomarker strategies to strengthen decision-making from early discovery through clinical development. Gain practical insights into harmonising biomarker assays, reducing reliance on lumbar puncture, generating regulatory-ready biomarker data and implementing scalable biomarker programmes that are accelerating the development of CNS therapeutics. URLs:Tickets: https://go.evvnt.com/3770065-1?pid=5569Brochure: https://go.evvnt.com/3770065-3?pid=5569 Date and Time: On Mon, 30 Nov 2026 08:00 - Wed, 02 Dec 2026 17:00 Venue Details: Hilton London Olympia, 380 Kensington High Street, London, England, W14 8NL, United Kingdom Category: Conferences Prices:Conference + Workshop Day - Drug Developer Pricing: GBP 3097.00,Conference Only - Drug Developer Pricing: GBP 2299.00,Conference + Workshop Day - Academic Pricing: GBP 2547.00,Conference Only - Academic Pricing: GBP 1899.00,Conference + Workshop Day - Solution Provider Pricing: GBP 4497.00,Conference Only - Solution Provider Pricing: GBP 3199.00 Speakers: Jens Mikkelsen Professor, Neuroscience University of Copenhagen, Jordi Clarimon Director, Biomarker Lead Specialist Lundbeck, Isabella Premoli Director, Translational Medicine Saniona, Nanh Nguyen Translational Medicine Biomarker Lead UCB, Sarah Almond Vice President, Translational Biology NRG Therapeutics, Jessica Nakhle Director, Head of Clinical Biomarkers Neuroscience and Immuno-inflammation, Translational Medicine Servier, Aleksandra Zemla Clinical Biomarkers Consultant Dompe, Tauseef Butt President and Chief Executive Officer Progenra Inc, Joseph Sutton Biomarker Studies Asset Manager Roche, Valerie Daggett Founder and Chief Executive Officer AltPep Corporation, Elia Hall Senior Scientist, Biosample Project Leader Roche, Amelie Schreieck Senior Manager, Biomarker Development Immunic Therapeutics, Wolfgang Liedtke Professor, Neurology Duke University, Nuno Pires Senior Manager Rare Diseases and Modalities In Vivo Pharmacology and Translation Bial, Lluis Riera Ponsati Director, Preclinical Development Neumirna Therapeutics, Kiri Granger Co-Founder and Chief Scientific Officer Monument Therapeutics, Kuti Baruch Vice President, Research and Development ImmunoBrain